On August 26th, Zhenbao Island released its semi-annual report for 2024, which showed that the company achieved a revenue of 1.66 billion yuan in the first half of 2024, and a net profit attributable to the shareholders of the listed company of 393 million yuan, a year-on-year increase of 281.93%. The company's pharmaceutical industry revenue grew by approximately 61%. Amidst the continuous turbulence and restructuring of the pharmaceutical industry, key financial indicators have shown an encouraging growth trend.

In recent years, the national support for the traditional Chinese medicine (TCM) industry has significantly increased, with the issuance of multiple policies and measures conducive to the development of TCM. Guided by favorable policies, Zhenbao Island Pharmaceutical has actively invested in research and development, enhanced its product innovation capabilities, and promoted continuous improvement in corporate marketing, further consolidating the company's position in the TCM industry. During the reporting period, the company scientifically planned and participated in national and provincial centralized procurement projects, continuously strengthening its market access capabilities, and the increase in marketing performance has driven the growth of both revenue and net profit.

Advertisement

Thanks to the company's outstanding advantages in bidding and centralized procurement, Zhenbao Island's core Chinese patent medicine varieties, such as the 100mg injection of Xuesaitong, Thrombus Tong capsules, Compound Qinlan oral liquid, and Shuanghuanglian oral liquid, have successfully been included in the "3+n" volume procurement project in the Beijing-Tianjin-Hebei region and have been implemented in multiple provinces. Chemical medicine varieties such as Granulated Amikacin capsules, Amikacin injection, and 200mg Yanhuning injection have also been included in the centralized procurement projects of various provinces one after another. This has further expanded the market share of products, obtained incremental advantages in scale, and effectively promoted the penetration of product terminals and sales channels. It has also consolidated the company's leading position in the market for similar products, deepened the layout and penetration of products in related regions, expanded the hinterland market, and become a new growth point for the company's performance, promoting a further increase in profitability and having a positive impact on the continuous improvement of operating performance.

The year 2024 marks the beginning of the iterative and upgraded marketing work of Zhenbao Island Pharmaceutical, relying on the "six-in-one, six-awareness" business philosophy and system and mechanism innovation, and has fully achieved the quality improvement and innovation of market marketing work. By comprehensively building a market-oriented marketing system centered on customers and focusing on consolidating the back-end service support mechanism centered on the market, the company has further deepened the implementation of a market marketing model with refined investment as the core. With a further clarified business strategy of "investment attraction, merchant finding, and service provision," combined with the further refinement of the market based on product attributes, the company has achieved continuous expansion of market terminal coverage, allowing the company's marketing work to take solid steps towards high-quality development.

During the reporting period, the company has focused on improving the quality of refined service work and continuously improving customer satisfaction, promoting development through service, and promoting win-win cooperation. Relying on precise and extensive brand services, product services, promotional services, academic services, and after-sales services, the company meets the needs of customers for medical information resources, forms a positive interaction with the demand for drug supply, and ensures the safety of public medication. Continuously improving market coverage and share, achieving steady operation of the existing stock market and rapid expansion of incremental business.

In recent times, according to research reports from multiple institutions, with the continuous adjustment of the pharmaceutical sector in 2024, it is expected to re-enter an upward trend. With the continuous advancement and implementation of national and inter-provincial alliance centralized procurement, companies with outstanding market access capabilities, deep cultivation of Chinese herbal medicine layout, intelligent manufacturing, and effective results in evidence-based research are expected to continue to benefit. Relying on marketing advantages, the dual growth of Zhenbao Island Pharmaceutical's revenue and net profit attributable to the parent undoubtedly injects a strong stimulant into the capital market. With the company's future centralized procurement advantages expected to further expand, the company's profitability is likely to continue to be enhanced, forming a virtuous development cycle, continuously forging operational resilience, and empowering long-term value enhancement.